Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Human rabies immune globulin · Kedrab

Plasma-derived product · Immune activation, directed at rabies virus · developed by Kamada

Approved FDA, Aug 2017
1 Registered trials

What is Human rabies immune globulin?

Human rabies immune globulin is a plasma-derived preparation of antibodies against rabies virus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kedrab
Drug type
Plasma-derived product
Targets
rabies virus
Mechanism
Immune activation, directed at rabies virus
Therapy area
Infectious disease
Developer
Kamada Ltd.
In trials of
GRFS
FDA status
Approved as Kedrab (August 23, 2017), BLA125613

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05382650 N/A Rabies Terminated GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PediatricsRabiesRabies HumanRabies Virus Infection

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.